Cabozantinib (XL184, BMS-907351)

Catalog No.S1119

Cabozantinib (XL184, BMS-907351) Chemical Structure

Molecular Weight(MW): 501.51

Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 470 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 27 Publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.
Targets
VEGFR2/KDR [1]
(Cell-free assay)
c-Met [1]
(Cell-free assay)
0.035 nM 1.3 nM
In vitro

XL184 has weak inhibitory activity against RON and PDGFRβ with IC50 of 124 nM and 234 nM, respectivey, and has low activity against FGFR1 with IC50 of 5.294 μM. [1] XL184 at low concentration (0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion. XL184 also induces marked inhibition of Met and VEGFR2 phosphorylation in cytokine-stimulated human umbilical vein endothelial cells (HUVECs). Although XL-184 has no significant effect on MPNST cell growth at 0.1 μM, XL184 at 5-10 μM significantly inhibits the MPNST cell growth. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
E98NT  MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\ISJkxNjBzLUGwJO69VQ>? Mm\pSG1UVw>? NVvOSGM4UUN3ME24PUBvVQ>? NV73Z|RMOjN2OESwNFY>
SNU-5  NFHme2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRSBzOTDuUS=> NYnBWINvOjF7Mk[xPVE>
Hs746T  NVLHUoZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPYbGdKSzVyPUmuPUBvVQ>? M1fPVFIyQTJ4MUmx
SNU-1  NVzieHFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTV{MkOgcm0> M1K5TlIyQTJ4MUmx
SNU-16 M{nlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXnTWM2OD1zMUS5JI5O M{XNRVIyQTJ4MUmx
MDA-MB-231 M4TRTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHZTWM2OD1iNkSyNUBvVQ>? MWeyNVkzPjF7MR?=
U87MG MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWWzW5VGUUN3ME2xPFUyKG6P M2\jWFIyQTJ4MUmx
H441  NVHUfGd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{C2SGlEPTB;MkG3NFAhdk1? M4KwNlIyQTJ4MUmx
H69 Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPQTWM2OD1{MEKwNEBvVQ>? M3rmUVIyQTJ4MUmx
PC3 MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjMbZBXUUN3ME2xNFgxOCCwTR?= NHqwblczOTl{NkG5NS=>
MTC-TT NVjmU|RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vH[GlEPTB;MD6wOEAsKDBwMEOg{txO MmfTNlE1PzB7OUW=
MZ-CRC NETaWIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRiB3IN88US=> MWCyNVQ4ODl7NR?=
TPC-1 NIrOTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\ydm9bUUN3ME2wMlA3KCtiMD6wNkDPxE1? NXf1UGVGOjF2N{C5PVU>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-MET(Y1234/1235) / MET / p-EGFR(Y1068) / EGFR / p-Gab1(Y627) / Gab1 / p-AKT(S473) / p-ERK / p-EIF4E; 

PubMed: 29188469     


MET kinase inhibitors but not emibetuzumab inhibited MET signaling pathway in Hs746t cells in vitro by western blot analysis. Hs746t cells were treated for 24 h with 133 nM (20 μg/ml) or 667 nM (100 μg/ml) emibetuzumab or MET kinase inhibitors (merestinib, PF04217903, crizotinib, cabozantinib) at 15.6, 62.5, 250 or 1000 nM.

p-MET / p-ERK / p-AKT; 

PubMed: 29520051     


Western blot analysis of cellular pathways modifications after CBZ 5 μM treatment in HOS, MG-63, Saos-2 and U-2 OS cells; (A) CBZ 5 μM inhibits c-MET phosphorilation after 1 hour of treatment; downstream ERK activation kinetic adopts a sigmoidal shape in all OS cell lines, whereas AKT activation is strongly inhibited in HOS, Saos-2 and U-2OS, but not in MG-63 cells.

29188469 29520051
Immunofluorescence
α-tubulin; 

PubMed: 29520051     


Immunostaining of mitotic spindle in control and CBZ 5 μM treated HOS cells using a monoclonal antibody against α-tubulin (in green); white arrows indicate the mitotic spindle poles; control cells show normal bipolar spindles during metaphase formation, whereas treated cells show tripolar spindles during prometaphase (II), metaphase (III) and anaphase (IV); bar scale = 10 μm.

29520051
Growth inhibition assay
Cell viability; 

PubMed: 23661005     


Cells were left untreated or were treated with 5, 7.5 or 10 μM cabozantinib (XL184). Seventy-two hours later viability was detected by MTT-assay and apoptosis by staining with annexinV-FITC followed by FACS-analysis.

23661005
In vivo XL184 treatment at 30 mg/kg in RIP-Tag2 mice with spontaneous pancreatic islet tumors disrupts 83% of the tumor vasculature, reduces pericytes and empty basement membrane sleeves, causes widespread intratumoral hypoxia and extensive tumor cell apoptosis, and slows regrowth of the tumor vasculature after drug withdrawal, more significantly compared with XL999 that blocks VEGFR but not c-Met, leading to only 43% reduction in vascularity, suggesting that concurrent inhibition of VEGFR and other functionally relevant receptor tyrosine kinases (RTK) amplifies angiogenesis inhibition. XL184 also decreases invasiveness of primary tumors and reduces metastasis. [1] XL184 at 30 mg/kg/day significantly abrogates human MPNST xenografts growth and metastasis in SCID mice. [2] Administration of XL184 induces dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models, in association with decreased tumor and endothelial cell proliferation as well as increased apoptosis. A single oral dose of XL184 is sufficient to induce sustained tumor growth inhibition in MDA-MB-231 tumor-bearing mice and C6 tumor-bearing rats at 100 mg/kg and 10 mg/kg, respectively. [3]

Protocol

Cell Research:

[2]

+ Expand
  • Cell lines: ST88-14, STS26T, and MPNST724
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 48 hours
  • Method:

    Cells are exposed to various concentrations of XL184 for 48 hours. Cell growth is determined by MTS assays using CellTiter96 Aqueous Non-Radioactive Cell Proliferation Assay kit. Absorbance is measured at a wavelength of 490 nm, and the absorbance values of treated cells are presented as a percentage of the absorbance of untreated cells.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: RIP-Tag2 transgenic mice in a C57BL/6 background with spontaneous pancreatic islet tumors
  • Formulation: Suspended at a concentration of 5 mg/mL in sterile saline or water
  • Dosages: ~60 mg/kg
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (199.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 501.51
Formula

C28H24FN3O5

CAS No. 849217-68-1
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04091750 Not yet recruiting Drug: Nivolumab|Drug: Ipilimumab|Drug: Cabozantinib Melanoma Georgetown University|MedStar Franklin Square Medical Center|Hackensack Meridian Health|Exelixis October 2019 Phase 2
NCT04066595 Not yet recruiting Drug: Cabozantinib Urothelial Carcinoma Johannes Gutenberg University Mainz|Interdisciplinary Center Clinical Trials (IZKS) University Medical Center Mainz September 30 2019 Phase 2
NCT03964337 Not yet recruiting Drug: Cabozantinib|Procedure: Radical Prostatectomy Prostate Cancer|Prostate Cancer Adenocarcinoma|Non-Metastatic Duke University|Exelixis September 2019 Phase 2
NCT03963206 Recruiting Drug: Cabozantinib group|Other: ECG Hepatocellular Carcinoma Hospices Civils de Lyon September 9 2019 Phase 4
NCT03696407 Completed -- Advanced Renal Cell Carcinoma Ipsen December 20 2018 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Cabozantinib (XL184, BMS-907351) | Cabozantinib (XL184, BMS-907351) supplier | purchase Cabozantinib (XL184, BMS-907351) | Cabozantinib (XL184, BMS-907351) cost | Cabozantinib (XL184, BMS-907351) manufacturer | order Cabozantinib (XL184, BMS-907351) | Cabozantinib (XL184, BMS-907351) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID